Table 2. Summary of Outcome Effect Sizes.
| Reference | Outcome Measurea | Basal cell carcinomab | Squamous Cell Carcinomab | Adjustments/Standardization |
|---|---|---|---|---|
| Studies included in meta-analysis | ||||
| Eisemann et al [44] | SMRc | 0.87 (0.86-0.87) | 1.17 (1.16-1.18) | Age, gender |
| Relative survival %, 10 year (SD) | 105.9% (0.2%) | 91.8% (0.5%) | Age, gender | |
| Jensen et al 2008 d [25] | SMR | 0.97 (0.96-0.98); M 0.98 (0.96-0.99); F 0.95 (0.94-0.97) | 1.30 (1.26-1.33); M 1.24 (1.21-1.28); F 1.39 (1.24-1.45) | Age, gender, 5 year calendar period |
| Rees et al [29] | HR | 0.96 (0.77-1.19) | 1.25 (1.01-1.54) | Age, gender, smoking, and subsequent cancer |
| Hollestein et al [6] | SMR | -- | 1.272673 (1.272669-1.272709)e | Age, gender, calendar year |
| Studies not included in meta-analysis | ||||
| Brondum-Jacobsen et al d [27] | HR | Combined: 0.52 (0.52-0.53) | Age, gender, descent, geographical residency, educational level, estimated occupational sun exposure, estimated occupational physical activity, and baseline characteristics. | |
| Fully adjusted OR | Combined: 0.97 (0.96-0.99) | |||
| Age adjusted OR | Combined: 0.96 (0.95-0.97) | Age | ||
| Clayman et al [47] | 3 year overall survival | -- | 70% (95% CI: 62-79) | None |
| Jensen et al 2010 d [34] | Crude 10 year MRR (95% CI) | 0.93 (0.91-0.94) | By age <60 1.85 (1.70-2.01), 60-70 1.20 (1.14-1.27), >70 1.11 (1.07-1.16) | None |
| Adjusted 10 year MRR (95% CI) | 0.91 (0.89-0.92) | By age <60 1.54 (1.41-1.68); 60-70 1.17 (1.10-1.23); >70 1.11 (1.07-1.15) | Age, gender, 23 comorbidities, and socioeconomic status | |
| 10 year cml mortality, % (95% CI) | 29.3 (28.9-29.6) | By age <60 27.0 (25.3-28.9), 60-70 54.5 (52.5-56.4), >70 80.5 (79.0-82.1) | ||
| Kahn et al [28] | RR | Combinedf: M 1.03 (1.00-1.06); F 1.04 (1.00-1.09) | Age, race, education level, smoking status, BMI, alcohol use, exercise, vegetable and fat intake, aspirin use, marital status, diabetes, menopausal status, parity, use of oral contraceptive pills and estrogen replacement therapy | |
| Karjalainen et al [23] | 5 year RSR | M 98.6; F 100.1 | M 90.4 (SE 2.9); F 89.9 (SE 2.8) | Gender, age at diagnosis, calendar time of diagnosis, histologic type, and anatomic site of the tumor |
| 10 year RSR | M 98.8; F 100.3 | M 87.2 (SE 4.4); F 83.3 (SE 4.0) | ||
| Robsahm et al [39] | 5 year RSR (95% CI) | -- | Localized SCC: M 0.82 (0.80-0.84), F 0.88 (0.85-0.90)g | Gender, age, stage |
| Teppo et al [45] | 5 year RSR | -- | M 90; F 92 | Age, gender, calendar time |
| Talback et al h [46] | 5 year RSR | -- | 87.8 | Gender, age, and calendar year |
| 10 year RSR | -- | 80 | ||
MRR= Mortality rate ratio; cml= cumulative; SMR= standardized mortality ratio; RSR= relative survival rate; HR= hazard ratio; OR= odds ratio
F= female; M= male
SMR calculated using absolute and relative 10-year survival data reported in article
Jensen 2008, Brondum-Jacobsen, and Jensen 2010 have overlapping study populations. Brondum-Jacobsen was included qualitatively because it provides a combined BCC/SCC estimate. Jensen 2010 was included qualitatively because it adjusted extensively for covariates.
Unpublished estimates provided by the authors
All non-melanoma skin cancers, which may include more rare cancers such as Merkel cell carcinoma
Displayed are results from 2000-2011, as this study splits results by decade. Listed is the result for localized SCC rather than ‘advanced’ SCC
Included ‘malignant skin cancer excluding melanoma’ in a cancer registry that does not collect BCC data